A5042956311- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
- Nanoplatforms for cancer theranostics
- interferon and immune responses
- Nanoparticle-Based Drug Delivery
- Chemical Reactions and Isotopes
- Immune cells in cancer
- Cell Image Analysis Techniques
- Computational Drug Discovery Methods
- Biosimilars and Bioanalytical Methods
- Cancer, Hypoxia, and Metabolism
- Advanced Biosensing Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Ferroptosis and cancer prognosis
- Cytokine Signaling Pathways and Interactions
- Immunotherapy and Immune Responses
- Ubiquitin and proteasome pathways
- RNA modifications and cancer
- Medical Imaging Techniques and Applications
- Tuberculosis Research and Epidemiology
- Metabolomics and Mass Spectrometry Studies
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
Presage Biosciences (United States)
2016-2024
Seattle University
2023
University of Louisville
1990-2019
Aberrant regulation of BCL-2 family members enables evasion apoptosis and tumor resistance to chemotherapy. functionally redundant counterpart, MCL-1, are frequently over-expressed in high-risk diffuse large B-cell lymphoma (DLBCL). While clinical inhibition has been achieved with the BH3 mimetic venetoclax, anti-tumor efficacy is limited by compensatory induction MCL-1. Voruciclib, an orally bioavailable stage CDK-selective inhibitor, potently blocks CDK9, transcriptional regulator Here, we...
Cancer drug development is currently limited by a paradigm of preclinical evaluation that does not adequately recapitulate the complexity intact human tumor microenvironment (TME). To overcome this, we combined trackable intratumor microdosing (CIVO) with spatial biology readouts to directly assess effects in patient tumors situ.In first-of-its-kind phase 0 clinical trial, explored an investigational stage SUMOylation-activating enzyme (SAE) inhibitor, subasumstat (TAK-981) 12 patients head...
Identification and treatment of chronic wounds (CWs) are considered economic social challenges, especially with respect to bedridden elderly persons. CWs do not follow a predictive course healing within particular period. Their management costs very high. Also, decrease quality life for patients, which cause severe pain discomfort. In this paper, we proposed comprehensive wound assessment framework based on current appearance, texture, prior visual appearance analysis handle different types...
Pressure ulcer (PU) is a type of chronic wounds (CWs), which remaining unhealed for period longer than six weeks. PU results from applying pressure and friction on the skin patient long time. It has complex structure as it different kinds tissues. Reliable assessment essential to success treatment care decision. In this paper, we propose tissue classification system based 3D convolutional neural network (CNN). The main idea proposed provide CNN with five models colored RGB images accurately...
Introduction: Drug development is systemically inefficient. Research and costs for novel therapeutics average hundreds of millions to billions dollars, with the overall likelihood approval estimated be as low 6.7% oncology drugs. Over half these failures are due a lack drug efficacy. This pervasive repeated rate success exemplifies how preclinical models fail adequately replicate complexity heterogeneity human cancer. Therefore, new methods evaluation, early in trajectory, essential both...
While advances in laboratory automation has dramatically increased throughout of compound screening efforts, development robust cell-based assays relevant disease models remain resource-intensive and time-consuming, presenting a bottleneck to drug discovery campaigns. To address this issue, we present modified gene trap approach efficiently generate pathway-specific reporters that result "on" signal when the pathway interest is inhibited. In proof-of-concept study, used vemurafenib...
2579 Background: TAK-676 is a novel synthetic STING agonist developed to induce an inflammatory state through release of interferon (IFN), production proinflammatory chemokines and cytokines, activation innate adaptive immune cells in the tumor microenvironment (TME). To gain early mechanistic insights on effects native TME alone combination with standard-of-care chemotherapies, we completed Phase 0 intratumoral microdosing trial head neck squamous cell carcinoma patients using Comparative...
<h3>Background</h3> Immune checkpoint inhibitors have produced durable clinical responses in hard-to-treat cancers, but to date, such are limited a minority of patients. Combination treatments PD-1 with drugs that target additional immune suppressive components the tumor microenvironment (TME) been proposed as solution. A resource-intensive approach investigating combinations (> 4500 trials date) has resulted success. more efficient evaluation drug is needed. CIVO<sup>®</sup> enables...
<p>Subasumstatinduces IFNβ in immune cells.</p>
<p>UMAP Cluster Analysis for Patients 7 and 8</p>
<p>Subasumstat induces interferon-response genes in a dose responsive fashion</p>
<p>Expression of IFNB1 and ISG15 as a function subasumstat exposure.</p>
<p>Subasumstat initiates cell death and cytotoxic T activity</p>
<p>FOV placement for SMI Analysis Patients 7 and 8 showing variation between sampled regions of the tumor</p>
<p>Subasumstat induces IFN response genes in CIVO micro-injected tumors</p>
<p>Correlation of MKI67 gene expression levels to Percent MIL113 Positivity for Tumors 7 and 8</p>
<p>Subasumstat Target Engagement Grading by MIL113 Staining</p>
<p>Percentages of Cells identified by UMAP analysis from Tumors 7 and 8</p>
<p>Spatial Reconstruction of Patient 7 and 8</p>